38,727 Shares in Grifols, S.A. (NASDAQ:GRFS) Bought by Atria Investments Inc

Atria Investments Inc bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 38,727 shares of the biotechnology company’s stock, valued at approximately $344,000.

Other large investors also recently modified their holdings of the company. Brandes Investment Partners LP lifted its stake in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after purchasing an additional 1,481,924 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Grifols by 18.7% during the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares in the last quarter. Capital World Investors boosted its stake in shares of Grifols by 4.9% during the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock valued at $138,605,000 after purchasing an additional 961,700 shares in the last quarter. Highland Peak Capital LLC purchased a new stake in Grifols during the second quarter valued at approximately $5,991,000. Finally, Black Creek Investment Management Inc. lifted its position in Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after acquiring an additional 881,155 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Trading Down 0.4 %

NASDAQ GRFS opened at $8.57 on Friday. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The company has a fifty day simple moving average of $8.86 and a two-hundred day simple moving average of $8.05. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.